At ESMO 2014, Prof Tom Powles (Barts Cancer Institute, UK) discusses strategies in the management of kidney cancer.
Recent clinical trials have increased interest in immunotherapy for kidney cancer. Results from a phase II study investigating the tyrosine kinase inhibitor, cediranib, in VEGF-resistant metastatic kidney cancer suggests a need for improved biomarkers, but developing clinically relevant biomarkers is challenging. Knowledge in the treatment of common kidney cancer subtypes have been applied in the rare papillary renal cell carcinoma subtype.